Application of ruxolitinib in preparation of medicine for treating intracranial fusiform aneurysm

• Main Authors: YA XIAOLONG, ZHAO JIZONG, ZHANG YAN, ZHENG ZHIYAO, MOU SIQI, LI HAO
• Format: Patent
• Language: Chinese; English
• Published: 24.10.2023
• Subjects: HUMAN NECESSITIES; HYGIENE; MEDICAL OR VETERINARY SCIENCE; PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES; SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS

The invention provides application of ruxolitinib in preparation of a medicine for treating intracranial fusiform aneurysm, and belongs to the technical field of biological medicine. According to the ruxolitinib disclosed by the invention, activation of a JAK2-STAT pathway is inhibited, phenotypic transformation of vascular smooth muscle cells caused by PDGFR beta Y562D gene mutation is reversed, and proliferation and migration capabilities of the vascular smooth muscle cells caused by the PDGFR beta Y562D gene mutation are weakened, so that the ruxolitinib has a certain treatment effect on occurrence and development of intracranial fusiform aneurysm. 本发明提供鲁索利替尼在制备治疗颅内梭形动脉瘤药物中的应用，属于生物医药技术领域。本发明所述鲁索利替尼抑制了JAK2-STAT通路的活化，逆转了PDGFRβY562D基因突变引起的血管平滑肌细胞表型转化，减弱了PDGFRβY562D基因突变引起的血管平滑肌细胞增殖和迁移能力，从而对颅内梭形动脉瘤的发生发展起到一定的治疗效果。